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 2 
ABSTRACT 35 
For Mycobacterial tuberculosis complex the rapid and accurate diagnosis of drug resistance is 36 
crucial to ensure early initiation of appropriate therapy. Recently a new molecular diagnostic 37 
test, the FluoroType® MTBDR aimed at detecting rifampicin and isoniazid resistance has 38 
become available. This study aimed to evaluate the FluoroType® MTBDR in comparison to 39 
phenotypic drug susceptibility testing (DST) using M. tuberculosis complex isolates. 40 
MTBC isolates underwent phenotypic DST and were tested using the FluoroType® MTBDR 41 
and Genotype MTBDRplus. Sanger sequencing of the key regions of rpoB, katG, inhA and 42 
aphC was performed for isolates with discordant phenotypic and molecular results. 43 
Furthermore isolates with specific wildtype bands missing in the Genotype MTBDRplus 44 
indicating the presence of a mutation were investigated by Sanger sequencing. Specificity and 45 
sensitivity defined as the proportion of isolates correctly determined as susceptible and resistant 46 
by the FluoroType® TBMDR compared to phenotypic DST were calculated.  47 
A total of 180 culture isolates were included; phenotypic DST showed 85 isolates susceptible 48 
to isoniazid and rifampicin, 7 with isoniazid mono-resistance, 7 with rifampicin mono-49 
resistance and 81 with multi-drug resistance. Specificity of the FluoroType® MTBDR was 50 
100% (95%CI 96.0-100%) for both rifampicin and isoniazid. Sensitivity was 91.7% (95%CI 51 
83.6-96.6%) for isoniazid and 98.9% (95%CI 93.8-100.0) for rifampicin.  52 
The FluoroType® MTBDR has a high sensitivity and specificity for the detection of rifampicin 53 
and isoniazid resistance when using culture isolates.  54 
 55 
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 3 
Introduction 65 
Rapid and accurate laboratory diagnosis of Mycobacterium tuberculosis drug susceptibility and 66 
resistance are crucial to ensure early initiation of appropriate therapy, to adequately manage 67 
disease and to control further transmission. Conventional drug susceptibility testing (DST) 68 
relies on culture-based methods with results only available after several weeks. Much shorter 69 
turn-around times can be achieved with molecular diagnostics either performed directly on 70 
sputum samples or positive cultures.
1-3
  71 
The currently available molecular methods include Xpert® MTB/RIF, line-probe assays 72 
(LPAs), Sanger target sequencing and next generation sequencing.
4-7
 LPAs are recommended 73 
by the World Health Organization (WHO) as rapid diagnostic tests for detection of drug 74 
resistance.
8
 The technology combines PCR with subsequent reverse hybridization. The 75 
specifically bound amplicons are made visible in a colorimetric detection reaction resulting in 76 
banding patterns suggestive of the presence or absence of mutations in the target genes. The 77 
most widely used LPA, the GenoType MTBDRplus, detects the most prevalent mutations in 78 
the rpoB, katG, inhA genes conferring resistance to rifampicin (RMP) and isoniazid (INH). The 79 
Genotype® MTBDRplus is designed to specifically detect four rpoB mutations (in codons 516, 80 
526 and 531), two katG mutations (in codon 315) and four inhA mutations in the regulatory 81 
region. Other mutations within the amplified region of the target genes are indicated by the 82 
absence of a wildtype band without the simultaneous presence of a mutation band.  83 
Recently a new assay, the FluoroType® MTBDR directed at the same target genes, but using a 84 
different technology has been developed. This assay combines a Linear-After-The-Exponential 85 
(LATE)–PCR9 together with special probes using lights-on/lights-off detection technology.10 86 
The readouts of the FluoroType® MTBDR are melting curves. The shapes correspond to 87 
wildtypes or the presence of specific mutations. The FluoroType® MTBDR is an open system, 88 
that identifies characterized mutation via a learning software interpreting the melting curves. 89 
Practically the FluoroType® MTBDR has several advantages over the Genotype® 90 
MTBDRplus i) less hands-on time ii) more rapid results ii) decreased risk of DNA 91 
contamination and iv) automatic interpretation with the possibility to import results directly 92 
into a laboratory information system. However, sensitivity and specificity for detecting RMP 93 
and INH resistance of this new method have not been investigated under routine conditions.  94 
This study aimed to compare the results of phenotypic DST, GenoType® MTBDRplus and 95 
FluoroType® MTBDR using cultures positive for M. tuberculosis complex.  96 
 97 
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 4 
Methods 99 
Mycobacterial cultures were performed at the National Mycobacterial Reference Laboratory in 100 
Borstel, Germany between May 2016 and October 2017 using mycobacterial growth indicator 101 
tubes (MGIT) (Becton Dickinson, USA) and Loewenstein-Jensen and Stonebrink culture slants 102 
(Artelt-Enclit, Germany). All cultures were identified to species level using the GenoType 103 
MTBC ver 1.X (Hain Lifescience, Nehren, Germany) according to the manufacturer’s 104 
instructions. The MGIT 960-Isoniazid-Rifampicin-Ethambutol (IRE) kit (Becton Dickison) 105 
was used according to the manufacturer’s instructions. The critical concentrations of 106 
Rifampicin and Isoniazid were 1 μg/ml and 0.1 μg/ml, respectively.11  107 
For DNA-extraction an aliquot of 500 µl was obtained from the bottom of a positive MGIT or 108 
two loops (10 µl) of bacterial growth were collected from Loewenstein-Jensen or Stonebrink 109 
culture slants and added to 500 µl of 0.9% NaCl solution. Samples were centrifuged at 3000 x 110 
g for 15 minutes. Supernatants were removed, and DNA extracted using the Fluorolyse® kit 111 
(Hain Lifescience, Nehren, Germany) according to the manufacturer’s instructions. In brief, 112 
100 µl of lysis buffer and 2 µl of internal control were added to the remaining pellets. The 113 
mixed samples were incubated at 95°C for 5 minutes, centrifuged for 1 min and resuspended in 114 
100 µl neutralization buffer. Following centrifugation at 10000 x g for 5 minutes supernatants 115 
were transferred into a 0.5 ml cryovial. DNA was stored at -20°C. For each batch, one negative 116 
control was included using 100 µl of lysis buffer, 100 µl of neutralization buffer and 2 µl of 117 
internal control. 118 
DNA was analysed with the Genotype MTBDRplus version 2 and FluoroType® MTBDR 119 
assays (Hain Lifescience, Nehren, Germany) as per manufacturer’s instructions. In brief, for 120 
the FluoroType® MTBDR 20 µl of DNA-solution was added to 6 µl master mix component A 121 
and 14 µl master mix component B and transferred into 96-well plates. Plates were then sealed, 122 
centrifuged and analyzed via FluoroCycler® 96. For each plate, one positive and one negative 123 
control were included. For the Genotype MTBDRplus version 2, 5 µl of DNA-solution were 124 
added to 45 µl of master mix, containing 10µl master mix component A and 35 µl component 125 
B. 20 µl of PCR-products were added to 20µl denaturation reagent in a hybridization well. 126 
Hybridization reagents were prepared, preheated and loaded onto the GT-Blotter® 48 (Hain 127 
Lifescience, Nehren, Germany). After an initial hybridization step, strips were added and 128 
hybridization performed as per standard protocol. For each batch, one negative control (45 µl 129 
master mix, 5 µl DNA free water) was tested. Interpretation of the results was performed 130 
according to the manufacturer’s instructions.  131 
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 5 
The package insert of the FluoroType® MTBDR identifies the following rpoB, katG and inhA 132 
mutations: T508A, S509T, E510H, L511P, S512K, Q513L, Q513P, Q513R, D516A, D516F, 133 
D516V, D516Y, N518I, S522L, S522Q, H526C, H526D, H526G, H526L, H526N, H526P, 134 
H526Q, H526R, H526S, H526Y, R529K, S531F, S531L, S531L, S531Q, S531W, L533E, 135 
L533P, S315T1, S315T2, S315N, S315R, G-17T, A-16G, C-15T, G-9A, T-8A, T-8C and T-136 
8G. In contrast the Genotype MTBDRplus is able to detect and specify the following 137 
mutations: D516V, H526Y, H526D, S531L, S315T1, S315T2, C-15T, A-16G, T-8C and T-8A. 138 
Molecular results were interpreted without knowledge of phenotypic DST results. Sanger 139 
sequencing in the key regions of rpoB, katG, inhA and aphC
12
 was performed for isolates with 140 
discordant results either between the two molecular methods or the molecular and phenotypic 141 
methods. If the Genotype MTBDRplus showed a missing wildtype band, but not mutation band 142 
Sanger sequencing in the respective key region was performed to confirm the FluoroType® 143 
MTBDR result. Sanger sequencing was performed using an ABI 3130xl genetic analyzer 144 
(Applied Biosystems) and an ABI BigDye Terminator cycle sequencing kit (version 3.1) 145 
according to the manufacturer's instructions.  146 
Molecular results were coded as wildtype, individual mutation, mutations in a region of the 147 
gene and indeterminate. Interpretation of molecular results was susceptible, resistant and 148 
indeterminate. Indeterminate results in the Genotype MTBDRplus were defined as detection of 149 
MTBC DNA without the presence of a gene locus controls. All samples yielding an 150 
indeterminate result were re-tested using a new aliquot of DNA. A mixed culture 151 
(heteroresistance) was defined as both wild-type and mutant DNA being present either 152 
identified by wild-type and mutant band (Genotype MTBDRplus) and/or respective double 153 
peaks in the DNA sequence. 154 
To determine the accuracy of the FluoroType® MTBDR assay, results were compared with 155 
phenotypic DST results. Sensitivity and specificity were calculated for RMP and INH 156 
separately. Sensitivity was defined as the proportion of isolates correctly determined as 157 
resistant by the FluoroType® MTBDR compared to the phenotypic DST results. Specificity 158 
was defined as the proportion of isolates correctly determined as susceptible by the 159 
FluoroType® MTBDR compared to the phenotypic DST results. McNemar test on paired 160 
proportions was used to compare sensitivity of the FluoroType® MTBDR and the Genotype 161 
MTBDRplus for INH. All statistical analysis were performed using Stata 14.0. 162 
Information was extracted from the laboratory information system anonymously. The ethics 163 
committee of the University of Luebeck approved the study. Individual consent was not sought 164 
as no additional patient information was obtained.  165 
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 6 
 166 
Results 167 
A total of 180 cultures were included in the study. The majority was identified as M. 168 
tuberculosis (n=173), followed by M. africanum (n=5), M. bovis ssp. bovis (n=1) and M. bovis 169 
var. BCG (n=1). Analysis of RMP and INH resistance included all isolates regardless of 170 
species. 85 isolates tested phenotypically susceptible for both RMP and INH, 7 were INH 171 
mono-resistant, 7 RMP mono-resistant and 81 resistant to both RMP and INH (table 1). The 172 
number of indeterminate results by FluoroType® MTBDR was 1 (0.6%) for rpoB, 2 (1.1%) for 173 
inhA and 6 for katG (3.3%) initially. Following repeated DNA extraction the number of 174 
indeterminate results was 0 (0.0%) for rpoB, 1 (0.6%) for inhA and 3 for katG (1.7%). 175 
Sensitivity of the FluoroType® MTBDR for INH was 91.7% (77/84, 95%CI 83.6-96.6) and 176 
specificity 100% (92/92, 96.1-100.0). For RMP the sensitivity was 98.9% (87/88, 95%CI 93.8-177 
100.0) and specificity 100.0% (90/90, 95%CI 96.0-100.0). The most frequent rpoB mutation 178 
detected by FluoroType® MTBDR was S531L (n=56). A total of 7 rpoB mutations remained 179 
unidentified. Mutations were identified by Sanger rpoB sequencing as H526L (n=3), S531L 180 
(n=1), Q513K (n=1), D516Y (n=1) and one mixed culture with a H526D and a S531L 181 
mutation. A total of four mixed culture were identified in the study. One of those cultures was a 182 
mixture of an rpoB wildtype isolate and an isolate with a L533P mutation. The FluoroType® 183 
MTBDR detected the L533P mutations while the Genotype MTBDRplus did not. The 184 
FluoroType® MTBDR identified three isolates as having H526P mutations while Sanger 185 
sequencing revealed H526L mutations. The FluoroType® MTBDR falsely detected an H526R 186 
mutation in a mixed culture with one isolate harboring a H526D and the other a S531L 187 
mutation. Of the seven cultures falsely tested as INH susceptible by the FluoroType® MTBDR 188 
four had katG and/or inhA mutations detected by the Genotype MTBDRplus. This resulted in a 189 
higher, but non-significant sensitivity of the MTBDRplus (96.0%; 95%CI 89.9-99.3) for INH 190 
compared to the FluoroType® MTBDR (91.7%; 95%CI 83.6-96.6) (p=0.12). 191 
 192 
Discussion 193 
This study shows high sensitivity and specificity of the FluoroType® MTBDR for the 194 
detection of RMP and INH resistance using M. tuberculosis complex isolates. The proportion 195 
of indeterminate results was small. Repeat DNA extraction resolved 5 of 9 indeterminate 196 
results suggesting that insufficient or low quality DNA might have been the problem. Two of 197 
the isolates that tested repeatedly indeterminate were mixed cultures which might explain the 198 
result.  199 
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 7 
For RMP, the sensitivity and specificity of FluoroType® MTBDR were comparable to those 200 
reported for established molecular diagnostics such as the Genotype MTBDRplus and the 201 
Xpert MTB/RIF.
2,3,13
 While the presence or absence of an rpoB mutation was correctly 202 
detected in all isolates, the FluoroType® MTBDR failed to identify the exact mutation in 10% 203 
(9/87) of cases. Given that silent rpoB mutations are rare,
14-16
 one might argue that detecting 204 
the presence of an rpoB mutation itself is sufficient. In fact, the most widely used molecular 205 
diagnostic test, the Xpert MTB/RIF only indicates the presence of RMP resistance without 206 
information about the associated rpoB mutation.  207 
The sensitivity of the FluoroType® MTBDR for detecting katG and/or inhA mutations was 208 
lower compared to the Genotype MTBDRplus. Two of the isolates falsely reported as INH 209 
susceptible by the FluoroType® MTBDR had a rare combination of mutations, a S315T1 katG 210 
mutation and a C-17T mutation in the inhA promotor region, one isolate had a T-8A mutation 211 
in the inhA promotor region. Theoretically the FluoroType® MTBDR has the potential for 212 
continuous improvement when new mutations and their respective melting curve properties are 213 
detected and fed back into the analytic software. Whether and how frequently improvement 214 
through software updates will occur remains to be seen.  215 
WHO recommends, that commercial molecular LPAs such as the Genotype MTBDRplus may 216 
be used for positive sputum smear specimen or a cultured isolate of M. tuberculosis complex to 217 
detect resistance to RMP and INH.
8
 The Genotype MTBDRplus offers benefit compared to 218 
phenotypic DST when used on cultured isolates. Firstly, results are available within 48 hours of 219 
the culture becoming positive in contrast to the 7-14 days to with culture-based DST.
17
 220 
Secondly, these assays are not affected by the presence of contamination with bacteria, fungi or 221 
non-tuberculosis mycobacteria, as are liquid culture-based DST systems. The Genotype 222 
MTBDRplus and FluoroType® MTBDR detect mutations in the same three target genes. 223 
However, there are some distinct advantages of the FluoroType® MTBDR. Except for DNA 224 
extraction, it provides a fully-automated, closed system with a capacity of testing 95 samples in 225 
one batch. This in turn decreases the risk of DNA contamination, which is less problematic 226 
when using DNA extracted from cultured isolates, but may be a significant problem when 227 
testing primary samples. Full automation also means less hands-on time and automated 228 
interpretation of results reducing the risk of analytic errors. Results can be directly imported 229 
into a laboratory information system thus decreasing transcription errors.  230 
This study has several strengths and limitations. It was conducted in a National Tuberculosis 231 
Reference Laboratory with standardized procedures for phenotypic and molecular DST and 232 
long-standing expertise with LPA and Sanger sequencing. Interpretation of molecular results 233 
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 8 
was performed blinded to the phenotypic DST results. Half of the isolates included in the study 234 
were resistant to both RMP and INH. However, the majority of isolates harbored the common 235 
S531L rpoB and S315T1 katG mutations, possibly skewing the sensitivity estimate upwards. 236 
In summary, the FluoroType® MTBDR assay testing culture isolates of M tuberculosis 237 
complex has a high sensitivity for detecting RMP resistance, but a lesser sensitivity for 238 
detection of INH resistance. It offers an alternative to the currently WHO-endorsed Genotype 239 
MTBDRplus especially for high throughput laboratories. However, validation studies from 240 
other settings are needed to ensure that isolates with a variety of mutations and combinations of 241 
mutations are investigated. Furthermore studies conducted in low- and middle-income 242 
countries with high burden of MDR-TB should be performed to assess the performance of the 243 
new test in those settings. 244 
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 10 
Table 1: Results of the FluoroType® MTBDR, GenoType MTBDRplus and phenotypic DST including all 180 isolates 313 
N 
FluoroType® MTBDR GenoType MTBDRplus 
Phenotypic 
DST 
Sanger Sequencing 
rpoB katG inhA 
Molecular DST 
Interpretation rpoB katG inhA 
Molecular DST 
Interpretation 
RMP INH RMP INH RMP INH rpoB katG inhA alpC 
85b WT WT WT S S WT WT WT S S S S     
6 WT S315T1 WT S R WT S315T1 WT S R S R   
  
1 WT WT C-15T S R WT WT C-15T S R S R     
1 WT S315T1 C-15T S R WT S315T1 C-15T S R R R 
Mutation 
outside the 
hotspot 
region 
   
3 S531L WT WT R S S531L WT WT R S R S     
1 S531L WT WT R S S531L WT WT R S R R   WT WT WT 
3 S531L WT WT R S 530-533 WT WT R S R S S531L    
1 S531L WT WT R S 530-533 WT WT R S R R S531L WT WT C-10T 
1 S531L WT WT R S S531L WT T-8A R R R R   T-8A  
1 S531L IND WT R IND S531L IND WT R IND R R  WT WT WT 
1 S531L MUT WT R R S531L S315T1 WT R R R R  S315T1   
2 S531L S315T2 WT R R S531L S315T2 WT R R R R     
2 S531L S315T1 C-15T R R S531L S315T1 C-15T R R R R     
1 S531L S315T1 C-15T R R 530-533 S315T1 C-15T R R R R S531L    
1 S531L S315T1 T-8C R R S531L S315T1 T-8C R R R R     
38 S531L S315T1 WT R R S531L S315T1 WT R R R R     
1 S531L S315T1 WT R R 530-533 S315T1 WT R R R R S531L    
5 D516V S315T1 WT R R D516V S315T1 WT R R R R     
1 D516V S315T1 WT R R 513-519 S315T1 WT R R R R D516V    
1a D516Y WT IND R IND 
513-519 
S531L 
IND C-15T R R R R 
D516Y 
S531L 
WT C-15T  
1c D516Y WT WT R S 513-519 S315T1 -15 to -17 R R R R D516Y S315T1 C-17T  
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 11 
3c H526D S315T1 WT R R H526D S315T1 WT R R R R     
1 H526D WT C-15T R R H526D WT C-15T R R R R     
1 H526D WT WT R S H526D WT WT R S R S     
1 H526N S315T1 WT R R 526-529 S315T1 WT R R R R H526N    
3 H526P S315T1 C-15T R R 526-529 S315T1 C-15T R R R R H526L    
1a H526R IND WT R IND 
H526D 
S531L 
S315T1 WT R R R R 
H526D 
S531L 
S315T1   
1 H526Y IND WT R IND H526Y S315T1 WT R R R R  S315T1   
2c H526Y S315T1 WT R R H526Y S315T1 WT R R R R     
1 H526Y WT WT R S H526Y S315T1 WT R R R R  S315T1   
1 L533P S315T1 T-8C R R 530-533 S315T1 T-8C R  R R L533P    
1a L533P S315T1 WT R R WT S315T1 WT S R R R 
WT      
L533P 
   
3c MUT S315T1 WT R R 526-529 S315T1 WT R R R R H526L    
1 MUT S315T1 WT R R 530-533 S315T1 WT R R R R S531L    
1 MUT S315T1 WT R R 510-517 S315T1 WT R R R R Q513K    
1a MUT WT WT R S 
H526D 
S531L 
WT WT R S R R H526D 
S531L 
WT WT WT 
1c MUT WT WT R S 513-519 S315T1 -15 to -17 R R R R D516Y S315T1 C-17T  
 314 
DST, drug susceptibility testing; RMP, rifampicin; INH, isoniazid; WT, wildtype; S, susceptible; R, resistant; IND, indeterminate; MUT, unidentified mutation;  315 
when wildtype bands were missing in the Genotype MTBDRplus assay the base-pair region is indicated (i.e. 526-529) ;  316 
amixed cultures; bone M. bovis ssp. bovis and one M. bovis var. BCG included, cone M africanum included,  317 
 318 
 319 
 320 
  321 
 322 
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